

Virtual Boardroom

Limited to 25 Participants Only

RESERVE YOUR SEAT TODAY!



26th April 2023 (Wednesday)



8am-10am PST / 11am-1pm EST /
4pm-6pm UK

Accelerate Drug Discovery with AI-driven Drug Design

Expiring patents and unmet patient needs demand faster and better innovation in Drug Discovery. An impactful method is to augment physical research experimentation with Artificial Intelligence (AI) and Machine Learning (ML) in drug design. Leveraging internal and external scientific data for active learning allows organizations to focus on the most promising targets and reduce time-consuming and expensive physical testing. In this round table we will discuss how “bridging the gap between the virtual and the real” will impact drug discovery in the future. Join us to discuss how science and technology can advance discovery by using the virtual twin to accelerate drug design.

- ✔ Share experiences of leveraging AI and ML to accelerate drug design
- ✔ Understand how AI/ML can be combined with physical experiments to improve your current approach to drug design
- ✔ Discuss the benefits, hurdles and expectations of virtually augmented drug design

Moderator:



Jason Benedict - BIOVIA CEO & Vice President R&D, [Dassault Systèmes](#)

Jason is a broadly experienced software industry executive with 25 years of experience building rigorous internal company processes and high-performance teams supporting scientific software product development, quality assurance, and services. As Vice President of R&D, Mr. Benedict is responsible for defining and directing scientific software development strategies supporting modeling & simulation, informatics, and AI-driven insights that advance collaborative innovation for science-based industries. In his current role as BIOVIA CEO, Mr. Benedict has responsibility for BIOVIA's operations. Previously, Mr. Benedict served as Accelrys Solutions Consulting Director (2004-2008); Accelrys R&D Chief Architect (2008-2013); and BIOVIA Software Engineering Sr. Director (2013-2016). Mr. Benedict is a graduate of Carnegie Mellon University with a degree in Chemical Engineering, specialization in polymers and surface sciences, research history in catalysis.

About BIOVIA:

BIOVIA, a brand of Dassault Systèmes, provides a scientific collaborative environment for advanced biological, chemical and materials experiences that allows science-driven companies access, organize, analyze and share data in unprecedented ways throughout the product lifecycle in regulated and non-regulated environments. BIOVIA's sophisticated enterprise portfolio of Scientific Informatics, Molecular Modeling & Simulation, Data Science, Laboratory Informatics, Formulation Design, Life Sciences Quality & Compliance and Manufacturing Analytics helps drive innovation, increase productivity, improve quality and compliance, reduce costs and accelerate time to market. BIOVIA is committed to enhancing and speeding innovation, increasing productivity, improving quality and compliance, reducing costs and accelerating product development for pharma and biotech companies around the world."